372 related articles for article (PubMed ID: 32986965)
21. Gut Microbiome and Response to Cardiovascular Drugs.
Tuteja S; Ferguson JF
Circ Genom Precis Med; 2019 Sep; 12(9):421-429. PubMed ID: 31462078
[TBL] [Abstract][Full Text] [Related]
22. Imbalance of gut microbiome and intestinal epithelial barrier dysfunction in cardiovascular disease.
Lezutekong JN; Nikhanj A; Oudit GY
Clin Sci (Lond); 2018 Apr; 132(8):901-904. PubMed ID: 29712884
[TBL] [Abstract][Full Text] [Related]
23. Coronary heart disease and intestinal microbiota.
Liu L; He X; Feng Y
Coron Artery Dis; 2019 Aug; 30(5):384-389. PubMed ID: 31276455
[TBL] [Abstract][Full Text] [Related]
24. The gut microbiome and elevated cardiovascular risk in obesity and autoimmunity.
Kasselman LJ; Vernice NA; DeLeon J; Reiss AB
Atherosclerosis; 2018 Apr; 271():203-213. PubMed ID: 29524863
[TBL] [Abstract][Full Text] [Related]
25. Targeting gut barrier dysfunction with phytotherapies: Effective strategy against chronic diseases.
Dey P
Pharmacol Res; 2020 Nov; 161():105135. PubMed ID: 32814166
[TBL] [Abstract][Full Text] [Related]
26. Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
Henning RJ; Bourgeois M; Harbison RD
Cardiovasc Toxicol; 2018 Dec; 18(6):493-506. PubMed ID: 29968072
[TBL] [Abstract][Full Text] [Related]
27. The gut microbiome and cardiovascular disease: current knowledge and clinical potential.
Ahmad AF; Dwivedi G; O'Gara F; Caparros-Martin J; Ward NC
Am J Physiol Heart Circ Physiol; 2019 Nov; 317(5):H923-H938. PubMed ID: 31469291
[TBL] [Abstract][Full Text] [Related]
28. Potential mechanisms for the emerging link between obesity and increased intestinal permeability.
Teixeira TF; Collado MC; Ferreira CL; Bressan J; Peluzio Mdo C
Nutr Res; 2012 Sep; 32(9):637-47. PubMed ID: 23084636
[TBL] [Abstract][Full Text] [Related]
29. Polyphenolic Compounds and Gut Microbiome in Cardiovascular Diseases.
McGrail L; Garelnabi M
Curr Pharm Biotechnol; 2020; 21(7):578-586. PubMed ID: 31713494
[TBL] [Abstract][Full Text] [Related]
30. The Effects of Prebiotic Supplementation with OMNi-LOGiC
Obermüller B; Singer G; Kienesberger B; Klymiuk I; Sperl D; Stadlbauer V; Horvath A; Miekisch W; Gierschner P; Grabherr R; Gruber HJ; Semeraro MD; Till H; Castellani C
Nutrients; 2020 Jul; 12(7):. PubMed ID: 32650568
[TBL] [Abstract][Full Text] [Related]
31. Gut microbiome and cardiovascular disease.
Zhao Y; Wang Z
Curr Opin Cardiol; 2020 May; 35(3):207-218. PubMed ID: 32068612
[TBL] [Abstract][Full Text] [Related]
32. Connecting the immune system, systemic chronic inflammation and the gut microbiome: The role of sex.
Rizzetto L; Fava F; Tuohy KM; Selmi C
J Autoimmun; 2018 Aug; 92():12-34. PubMed ID: 29861127
[TBL] [Abstract][Full Text] [Related]
33. Human microbiome as therapeutic intervention target to reduce cardiovascular disease risk.
Koopen AM; Groen AK; Nieuwdorp M
Curr Opin Lipidol; 2016 Dec; 27(6):615-622. PubMed ID: 27676197
[TBL] [Abstract][Full Text] [Related]
34. A Polysaccharide Isolated from Dictyophora indusiata Promotes Recovery from Antibiotic-Driven Intestinal Dysbiosis and Improves Gut Epithelial Barrier Function in a Mouse Model.
Kanwal S; Joseph TP; Owusu L; Xiaomeng R; Meiqi L; Yi X
Nutrients; 2018 Jul; 10(8):. PubMed ID: 30065236
[TBL] [Abstract][Full Text] [Related]
35. Metabolic endotoxemia and cardiovascular disease: A systematic review about potential roles of prebiotics and probiotics.
Moludi J; Maleki V; Jafari-Vayghyan H; Vaghef-Mehrabany E; Alizadeh M
Clin Exp Pharmacol Physiol; 2020 Jun; 47(6):927-939. PubMed ID: 31894861
[TBL] [Abstract][Full Text] [Related]
36. Gut hormones and gut microbiota: implications for kidney function and hypertension.
Afsar B; Vaziri ND; Aslan G; Tarim K; Kanbay M
J Am Soc Hypertens; 2016 Dec; 10(12):954-961. PubMed ID: 27865823
[TBL] [Abstract][Full Text] [Related]
37. Exercise, intestinal barrier dysfunction and probiotic supplementation.
Lamprecht M; Frauwallner A
Med Sport Sci; 2012; 59():47-56. PubMed ID: 23075554
[TBL] [Abstract][Full Text] [Related]
38. High-Throughput Screen Identifies Host and Microbiota Regulators of Intestinal Barrier Function.
Grosheva I; Zheng D; Levy M; Polansky O; Lichtenstein A; Golani O; Dori-Bachash M; Moresi C; Shapiro H; Del Mare-Roumani S; Valdes-Mas R; He Y; Karbi H; Chen M; Harmelin A; Straussman R; Yissachar N; Elinav E; Geiger B
Gastroenterology; 2020 Nov; 159(5):1807-1823. PubMed ID: 32653496
[TBL] [Abstract][Full Text] [Related]
39. Glutamine and intestinal barrier function.
Wang B; Wu G; Zhou Z; Dai Z; Sun Y; Ji Y; Li W; Wang W; Liu C; Han F; Wu Z
Amino Acids; 2015 Oct; 47(10):2143-54. PubMed ID: 24965526
[TBL] [Abstract][Full Text] [Related]
40. Aberrant Gut Microbiome Contributes to Intestinal Oxidative Stress, Barrier Dysfunction, Inflammation and Systemic Autoimmune Responses in MRL/lpr Mice.
Wang H; Wang G; Banerjee N; Liang Y; Du X; Boor PJ; Hoffman KL; Khan MF
Front Immunol; 2021; 12():651191. PubMed ID: 33912174
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
